BMS, Ono expand cancer immunotherapy pact
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Ono Pharmaceuticals are joining up under a collaborative deal to develop a number of immunotherapies for various cancer indications in Japan, South Korea and Taiwan.
You may also be interested in...
Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.